Ocugen, Inc.
$461.24M- Market cap
- $451.02M
- Debt
- +$28.79M
- Cash
- −$18.57M
Capital structure 94% equity / 6% debt · EV / Revenue 104.52x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $451.02M · View financials
Snapshot Sep 8, 2026, 1:51 PM ET
FY 2024 ·
Decision snapshot: OCGN stock price vs PGRE: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PGRE's multiple
Needs PGRE P/S.
Implied fair value · at OCGN's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OCGN FY 2025 (ended Dec 31, 2025) · PGRE FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
11 fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 104.52x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
OCUGEN, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
PARAMOUNT GROUP, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-2.37x
1.23x
Net debt / EBITDA
Leverage against operating earnings
-0.16x
28.53x
Cash and equivalents
Liquid reserves on the balance sheet
$18.57M
$375.06M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
IOVANCE BIOTHERAPEUTICS, INC.
OCGN vs IOVA
bluebird bio, Inc.
OCGN vs BLUE
BioNTech SE
OCGN vs BNTX
Moderna, Inc.
OCGN vs MRNA
Legend Biotech Corp
OCGN vs LEGN
Arcturus Therapeutics Holdings Inc.
OCGN vs ARCT
BXP, Inc.
OCGN vs BXP
SL GREEN REALTY CORP
OCGN vs SLG
VORNADO REALTY TRUST
OCGN vs VNO
KILROY REALTY CORP
OCGN vs KRC
ALEXANDRIA REAL ESTATE EQUITIES, INC.
OCGN vs ARE
$28.79M
$3.86B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.